GO Therapeutics appoints Dr. Robert J. Wills to Board of Directors CAMBRIDGE, Mass., Oct. 04, 2017 (GLOBE NEWSWIRE) -- GO Therapeutics, a company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer therapeutics against...

Antibody Drug Market Expected to Gain $30 Billion Through 2022 WELLESLEY, Mass. , Oct. 03, 2017 (GLOBE NEWSWIRE) -- An increase in research and development, burgeoning industry competition and evolving technologies are steering the antibody drug market into a...

Salubris Pharmaceuticals Invests $5 Million in GO Therapeutics CAMBRIDGE, Mass., Sept. 25, 2017 (GLOBE NEWSWIRE) -- GO Therapeutics today announced that Salubris Pharmaceutical Limited has made a $5M investment in GO Therapeutics, a Cambridge, MA-based company...

Market for Antibody Drug Conjugates to Reach $4.2B by 2021 WELLESLEY, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Technological advancements, the rising incidence of cancer, and an increasing demand for biologic therapies are driving the market for...